Acadia Pharmaceuticals Inc (Acadia) discovers, develops, and commercializes small-molecule drugs for the treatment of central nervous system (CNS) disorders and rare diseases. Its commercial product portfolio includes two FDA-approved drugs: NUPLAZID for Parkinson’s disease psychosis and DAYBUE for Rett syndrome. The company also provides specialized patient support services to assist with medication access and adherence.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Acadia is focused on advancing care in neurological disorders and rare diseases through research and development efforts. The company's R&D activities have primarily concentrated on product candidates such as pimavanserin, trofinetide, and remlifanserin, among others. The company is committed to conducting clinical trials and supporting development activities to seek regulatory approval for its product candidates. Acadia is also involved in post-marketing work, including clinical and nonclinical studies, as required by the FDA. The R&D activities of Acadia involve external service providers for manufacturing product candidates and conducting preclinical and clinical development. The internal research and development resources, including employees and discovery infrastructure, are utilized across several projects. The company allocates external expenses proportionally to each project when they are not attributable to a specific project. The pipeline products include Remlifanserin (ACP-204) for Alzheimer's Disease Psychosis and Lewy Body Dementia with Psychosis, ACP-211 for Major Depressive Disorder, ACP-711 for Essential Tremor, ACP-271 for Tardive Dyskinesia, ACP-2591 for Rett Syndrome and Fragile X Syndrome, ACP-271 for Huntington's Disease, and STOKE ASO for SYNGAP1. In FY2025, the company spent US$328.8 million on its R&D activities, which as a percentage of revenue stood at 30.6% and increased 8.44% YoY.